Celator has hired Fred Powell as chief financial officer.
He joins from OraPharma, and will be responsible for the oncology specialist’s accounting, corporate finance, financial planning, investor relations and administration functions.
“Fred brings a tremendous skill set and experience base to a company at our stage, with a 20-year track record in the biopharmaceutical industry that includes private and public financings, mergers and acquisitions, and domestic and global operations,” said Scott Jackson, CEO of Celator Pharmaceuticals.
“He will make an immediate and substantive contribution to our success.”
During his time at OraPharma, Powell helped the company through several transitions, helping to establish it as a stand-alone business after its sale by Johnson & Johnson in late 2010, and then supporting its acquisition by Valeant Pharmaceuticals in June, 2012.
Prior to joining OraPharma, he was the chief financial officer of BMP Sunstone Corporation, a US specialty pharmaceutical, overseeing its eventual sale to Sanofi.
Powell also held senior finance and administration positions at Eximias Pharmaceutical Corporation, Innaphase Corporation, and ERT (formerly EResearch Technology).